» Articles » PMID: 34000062

Constitutive Protein Kinase G Activation Exacerbates Stress-induced Cardiomyopathy

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2021 May 17
PMID 34000062
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Heart failure is associated with high morbidity and mortality, and new therapeutic targets are needed. Preclinical data suggest that pharmacological activation of protein kinase G (PKG) can reduce maladaptive ventricular remodelling and cardiac dysfunction in the stressed heart. However, clinical trial results have been mixed and the effects of long-term PKG activation in the heart are unknown.

Experimental Approach: We characterized the cardiac phenotype of mice carrying a heterozygous knock-in mutation of PKG1 (Prkg1 ), which causes constitutive, cGMP-independent activation of the kinase. We examined isolated cardiac myocytes and intact mice, the latter after stress induced by surgical transaortic constriction or angiotensin II (Ang II) infusion.

Key Results: Cardiac myocytes from Prkg1 mice showed altered phosphorylation of sarcomeric proteins and reduced contractility in response to electrical stimulation, compared to cells from wild type mice. Under basal conditions, young PKG1 mice exhibited no obvious cardiac abnormalities, but aging animals developed mild increases in cardiac fibrosis. In response to angiotensin II infusion or fixed pressure overload induced by transaortic constriction, young PKG mice exhibited excessive hypertrophic remodelling with increased fibrosis and myocyte apoptosis, leading to increased left ventricular dilation and dysfunction compared to wild type litter mates.

Conclusion And Implications: Long-term PKG1 activation in mice may be harmful to the heart, especially in the presence of pressure overload and neurohumoral stress.

Linked Articles: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc.

Citing Articles

The Efficacy of Risk Factor Modification Compared to NAD Repletion in Diastolic Heart Failure.

Koay Y, Liu R, McIntosh B, Vigder N, Lauren S, Bai A JACC Basic Transl Sci. 2024; 9(6):733-750.

PMID: 39070276 PMC: 11282886. DOI: 10.1016/j.jacbts.2024.01.011.


New Therapeutics for Heart Failure: Focusing on cGMP Signaling.

Mangmool S, Duangrat R, Parichatikanond W, Kurose H Int J Mol Sci. 2023; 24(16).

PMID: 37629047 PMC: 10454066. DOI: 10.3390/ijms241612866.


Clinical pharmacology of cardiac cyclic AMP in human heart failure: too much or too little?.

Lymperopoulos A Expert Rev Clin Pharmacol. 2023; 16(7):623-630.

PMID: 37403791 PMC: 10529896. DOI: 10.1080/17512433.2023.2233891.

References
1.
Burnett Jr J . Vericiguat - Another Victory for Targeting Cyclic GMP in Heart Failure. N Engl J Med. 2020; 382(20):1952-1953. DOI: 10.1056/NEJMe2006855. View

2.
Mizutani H, Okamoto R, Moriki N, Konishi K, Taniguchi M, Fujita S . Overexpression of myosin phosphatase reduces Ca(2+) sensitivity of contraction and impairs cardiac function. Circ J. 2009; 74(1):120-8. DOI: 10.1253/circj.cj-09-0462. View

3.
Yuen S, Ogut O, Brozovich F . Differential phosphorylation of LZ+/LZ- MYPT1 isoforms regulates MLC phosphatase activity. Arch Biochem Biophys. 2014; 562:37-42. DOI: 10.1016/j.abb.2014.08.011. View

4.
Kuhn M . Molecular Physiology of Membrane Guanylyl Cyclase Receptors. Physiol Rev. 2016; 96(2):751-804. DOI: 10.1152/physrev.00022.2015. View

5.
Chan M, Aminzai S, Hu T, Taran A, Li S, Kim C . A substitution in cGMP-dependent protein kinase 1 associated with aortic disease induces an active conformation in the absence of cGMP. J Biol Chem. 2020; 295(30):10394-10405. PMC: 7383375. DOI: 10.1074/jbc.RA119.010984. View